Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000019.xml
Fortschr Neurol Psychiatr 2010; 78(3): 169-183
DOI: 10.1055/s-0028-1109692
DOI: 10.1055/s-0028-1109692
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York
Therapieresistente Depressionen
Teil II: Psychopharmakologische Behandlungsstrategien, Hirnstimulations- und andere somatische TherapieverfahrenTreatment-Resistant DepressionPart II: Psychopharmacological Treatment, Strategies, Brain Stimulation and Other Somatic TreatmentoptionsFurther Information
Publication History
Publication Date:
07 September 2009 (online)
![](https://www.thieme-connect.de/media/fdn/201003/lookinside/thumbnails/10.1055-s-0028-1109692-1.jpg)
Lernziele
Kenntnis über
wichtige psychopharmakologische Behandlungsstrategien (Hochdosierung, Switching, Kombinationstherapien, Augmentationstherapien) bei therapieresistenten Depressionen Hirnstimulationsverfahren (EKT, rTMS, VNS) Schlafentzugs- und Lichttherapie
Literatur
- 1 Möller H J. Therapieresistenz auf Antidepressiva. Nervenarzt. 2004; 75 499-517
- 2 Möller H J. Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression. Psychopharmakotherapie. 2004; 11 34-41
- 3 Souery D, Papakostas G I, Trivedi M H. Treatment-resistant depression. J Clin Psychiatry. 2006; 67 (Suppl 6) 16-22
- 4 Adli M, Baethge C, Heinz A. et al . Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005; 255 387-400
- 5 Harrison C L, Ferrier N, Young A H. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol. 2004; 18 200-204
- 6 Thase M E, Shelton R C, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006; 26 250-258
- 7 Thase M E, Rush A J. When at first you don’t succeed: sequential strategies for antidepressant nonresponsers. J Clin Psychiatry. 1997; 58 (Suppl 1) 23-29
- 8 Thase M E, Feighner J P, Lydiard R B. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry. 2001; 62 683-687
- 9 Fava M, McGrath P J, Sheu W P. et al . Switching fluoxetine to reboxetine: an efficacy and safety study in depressed patients resistant to fluoxetine (abstract p03.198). Int J Neuropsychopharmacol. 2000; 3 234
- 10 Thase M E, Rush A J. Treatment-resistant depression. Bloom FE, Kupfer DJ Psychopharmacology: the fourth generation of progress New York; Raven Press 1995: 1081-1097
- 11 AHCPR .Depression Guidelines Panel-Depression in primary care: Clinical practice guideline no. 5 AHCPR pub No 93 – 0550,. Rockville MD 1993
- 12 Rush A J, Trivedi M H, Wisniewski S R. et al . Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354 1231-1242
- 13 Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. J Affect Disord. 2006; 95 129-133
- 14 Dodd S, Horgan D, Malhi G. et al . To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord. 2005; 89 1-11
- 15 Schmauß M, Messer T. Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?. Fortschr Neurol Psychiat. 2009; 77 316-325
- 16 Schmauß M, Messer T. Polypharmazie in der Behandlung depressiver Störungen. Messer T, Schmauß M Polypharmazie in der Behandlung psychischer Erkrankungen Wien, New York; Springer 2009; im Druck 2. Aufl
- 17 Bauer M, Linden M. Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen. Nervenarzt. 1993; 64 343-347
- 18 Frye M A, Ketter T A, Leverich G S. et al . The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000; 61 9-15
- 19 Murphy D L, Sunderland T, Cohen R M. Monoamine oxidase-inhibiting antidepressants – a clinical update. Psychiatr Clin North Am. 1984; 7 549-562
- 20 Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry. 1971; 24 509-514
- 21 Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka. Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer, Wien, New York; 2002 2. Aufl: 551-557
- 22 Steinberg R, Jost C, Weess H G. et al . Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome data in therapy resistant MD. Neuropsychopharmacology (Suppl). 1994; 10 62
- 23 Koenig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry. 1997; 30 93-96
- 24 Neuvonen P, Pohjola-Sintonen S, Tacke U. et al . Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993; 342 1419
- 25 Hawley C J, Quick S J, Ratnam S. Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. Int Clin Psychopharmacol. 1996; 11 187-191
- 26 Dams R, Benijts T H, Lambert W E. et al . A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol. 2001; 25 147-151
- 27 Volz H P, Gleiter C H, Möller H J. Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt. 1996; 67 339-347
- 28 Baron B M, Ogden A, Seigel B W. et al . Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol. 1988; 154 125-134
- 29 Nelson J C. Augmentation strategies with serotonin-noradrenergic combinations. J Clin Psychiatry. 1998; 59 65-68
- 30 Nelson J C, Mazure C M, Browers M BJ. et al . A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991; 48 303-307
- 31 Dam J, Ryde L, Svejso J. et al . Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry. 1998; 31 48-54
- 32 Ferreri M, Lavergne F, Berlin I. et al . Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001; 103 66-72
- 33 Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord. 1996; 41 201-210
- 34 Harkin A, Kelly J P, McNamara M. et al . Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol. 1999; 364 123-132
- 35 Carpenter L L, Yasmin S, Price H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002; 51 183-188
- 36 Debonnel G, Gobbi G, Turcotte J. et al .The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th ACNP Meeting, Dec 10 – 14, San Juan, Puerto Rico, 2002.
- 37 Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter). J Clin Psychiatry. 1999; 60 260-261
- 38 McGrath P J, Stewart J W, Fava M. et al . Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report. Am J Psychiatry. 2006; 163 1531-1541
- 39 Lam R W, Hossie H, Solomons K. et al . Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004; 65 337-340
- 40 Papakostas G I, Worthington J J, Iosifescu D V. et al . The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 3 178-181
- 41 DeBattista C, Solvason H B, Poirier J. et al . A prospective trial of bupropion SR augmentation of partial and non-responsers to serotonergic antidepressants. J Clin Psychopharmacol. 2003; 23 27-30
- 42 Zisook S, Rush A J, Haight B R. et al . Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006; 59 203-210
- 43 Trivedi M H, Fava M, Wisniewski S R. et al . Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 12 1243-1252
- 44 Lam R W, Wan D D, Cohen N L. et al . Combining antidepressants for treatment-resistant depression. A review. J Clin Psychiatry. 2002; 63 685-693
- 45 Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry. 2001; 2 57-67
- 46 Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. Teil I. Nervenarzt. 1993; 64 1-10
- 47 Crossley N A, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2007; 68 935-940
- 48 Bauer M, Forsthoff A, Baethge C. et al . Lithium augmentation therapy in refractory depression – update 2002. Eur Arch Psychiatry Clin Neurosci. 2003; 253 132-139
- 49 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2001; 34 119-127
- 50 Shelton R C, Papakostas G I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008; 117 253-259
- 51 Shelton R C, Williamson D J, Corya S A. et al . Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005; 66 1289-1297
- 52 Corya S A, Williamson D, Sanger T M. et al . A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety. 2006; 23 364-372
- 53 Papakostas G I, Shelton R C, Smith J. et al . Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007; 68 826-831
- 54 Warneke L. Psychostimulants in psychiatry. Can J Psychiatry. 1990; 35 3-10
- 55 Robertson Jr P, Hellriegel E T. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003; 42 123-137
- 56 Ninan P T, Hassman H A, Glass S J. et al . Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry. 2004; 65 414-420
- 57 Landen M, Bjorling G, Agren H. et al . A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. J Clin Psychiatry. 1998; 59 664-668
- 58 Sachs G, Collins M A, Altshuler L. et al .Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary Washington DC 2002
- 59 Barbee J G, Jamhour N J. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002; 63 (Suppl 8) 737-741
- 60 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry. 1998; 59 (Suppl 5) 51-58
- 61 Cassano P, Lattanzi L, Fava M. et al . Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005; 50 357-360
- 62 Dawson L A, Nguyen H Q. The role of 5-HAT(1A) and 5-HAT(1B/ 1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (+ /–) pindolol. Neuropharmacology. 2000; 39 1044-1052
- 63 Olver J S, Cryan J F, Burrows G D. et al . Pindolol augmentation of antidepressants: a review and rationale. Aust N Z J Psychiatry. 2000; 34 71-79
- 64 Erfurth A, Möller H J. Vorgehen bei Antidepressiva-Nonrespondern. Möller HJ Therapie psychiatrischer Erkrankungen Stuttgart, New York; Thieme 2000 2. Aufl: 407-412
- 65 Abrams R. Electroconvulsive Therapy. Oxford, New York; Oxford University Press 2002
- 66 Pagnin D, Queiroz de V, Pini S. et al . Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004; 20 13-20
- 67 American Psychiatric Association (APA) . Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000; 157 1-45
- 68 National Institute for Clinical Excellence .Depression: Management of depression in primary and secondary care. Clinical Guidelines 2004 23 http://www.nice.org.uk/CGO23 NICEguideline
- 69 UK ECT Review-Group . Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003; 361 799-808
- 70 Bourgon L N, Kellner C H. Relapse of depression after ECT: a review. J ECT. 2000; 16 19-31
- 71 O’Reardon J P, Solvason H B, Janicak P G. et al . Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62 1208-1216
- 72 Rush A J, George M S, Sackeim H A. et al . Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000; 47 276-286
- 73 Kuhn J, Huff W, Lee S H. et al . Tiefenhirnstimulation bei psychiatrischen Erkrankungen. Fortschr Neurol Psychiat. 2007; 75 447-457
- 74 Golden R N, Gaynes B N, Ekstrom R D. et al . The efficacy of light therapy in the treatment of mood disorders. A review and meta-analysis of the evidence. Am J Psychiatry. 2005; 62 656-662
- 75 Kennedy S H, Lam R W, Cohen N L. et al . Clinical guidelines for the treatment of depressive disorders. IV: Medications and other biological treatments. Can J Psychiatry. 2001; 46 38-58
- 76 Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005 2. Aufl: 3-19
- 77 Adli M, Rush A J, Möller H J. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry. 2003; 36 222-229
- 78 Adli M, Bauer M, Rush A J. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry. 2006; 59 1029-1038
- 79 Trivedi M H, Rush A J, Crismon M L. et al . Texas Medication Algorithm Project (TMAP): Clinical results for patients with major depressive disorder. Arch Gen Psychiatry. 2004; 61 669-680
- 80 DGPPN .S3-Leitlinie zur Behandlung depressiver Störungen. Darmstadt; Steinkopff 2009; im Druck
- 81 Canadian Psychiatric Association . Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001; 46 (Suppl 1) 13-90
- 82 Menke R, Gaebel W. Leitlinienkonformität in Klinik und Praxis. Psychopharmakotherapie. 2005; 12 (Suppl 13) 3-7
- 83 Bauer M, Whybrow P C, Angst J. et al .Biologische Behandlung unipolarer depressiver Störungen, Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart; Wissenschaftliche Verlagsgesellschaft 2004
Prof. Dr. med. M. Schmauß
Ärztlicher Direktor, Bezirkskrankenhaus Augsburg
Dr.-Mack-Straße 1
86156 Augsburg
Email: m.schmauss@bkh-augsburg.de